References
1. Ferrándiz C, Carrascosa JM, Toro M. Prevalencia de la psoriasis en España en la era de los agentes biológicos. Actas Dermosifiliogr 2014; 105: 504-9.
2. Garshick MK, Kimball AB. Psoriasis and the life cycle of persistent life effects. Dermatol Clin 2015; 33: 25-39.
3. Ji J, Shu X, Sundquist K, et al. Cancer risk in hospitalised psoriasis patients: a follow-up study in Sweden. B J Cancer 2009; 100: 1499-1502.
4. Woo WK, McMillan SA, Watson RGP, et al. Coeliac disease-associated antibodies correlate with psoriasis activity. B J Dermatology 2004; 151: 891-894.
5. Cohen AD, Dreiher J, Birkenfeld S. Psoriasis associated with ulcerative colitis and Crohn’s disease. J Eur Acad Dermatol Venerol 2009; 23: 561-565.
6. Jensen P, Egeberg A, Gislason G, et al. Increased risk of autoimmune hepatitis in patients with psoriasis: A Danish nationwide cohort study. J Invest Dermatol 2016; 136: 1515-1517.
7. Lonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI.ST.E.N.A. study. Dig Liver Dis 2001; 33: 86-7.
8. Miele L, Vallone S, Cefalo C et al. Prevalence, characteristics and severity of non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 778-786.
9. Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol 2009; 51: 758-764.
10. van der Voort EA, Koehler EM, Nijsten T, et al. Increased prevalence of advanced liver fibrosis in patients with psoriasis: A cross-sectional analysis from the Rotterdam study. Acta Derm Venereol 2016; 96: 213-217.
11. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 2015; 30: 282-287.
12. Roberts KK, Cochet AE, Lamb PB, et al. The prevalence of NAFLD and NASH among patients with psoriasis in a tertiary care dermatology and rheumatology clinic. Aliment Pharmacol Ther 2015; 41: 293-300.
13. Xu X, Su L, Gao Y, et al. The prevalence of nonalcoholic fatty liver disease and related metabolic comorbidities was associated with age at onset of moderate to severe plaque psoriasis: A cross-sectional study. PLoS One 2017; 12: e0169952.
14. Awosika O, Eleryan MG, Rengifo-Pardo M, et al. A case-control study to evaluate the prevalence of nonalcoholic fatty liver disease among patients with moderate-to-severe psoriasis. J Clin Aesthet Dermatol 2018; 11: 33-37.
15. Candia R, Ruiz A, Torres-Robles R, et al. Risk of non-alcoholic fatty liver disease in patients with psoriasis: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol 2015; 29: 656-62.
16. Abedini R, Salehi M, Lajevardi V, et al. Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease. Clin Exp Dermatol 2015; 40:722-7.
17. Yang YW, Keller JJ, Lin HC. Medical comorbidity associated with psoriasis in adults: a population-based study. Br J Dermatol 2011; 165: 1037-43. doi: 10.1111/j.1365-2133.2011.10494.x.
18. Gisondi P, Barba E, Girolomoni G. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 2016; 30:282-7.
19. van der Voort EA, Koehler EM, Dowlatshahi EA, et al. Psoriasis is independently associated with nonalcoholic fatty liver disease in patients 55 years old or older: Results from a population-based study. J Am Acad Dermatol 2014; 70:517-24.
20. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328-357.
21. Sommer DM, Jenisch S, Suchan M, et al. Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-328.
22. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: A hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
23. Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 2013; 10: 330-344.
24. Lonardo A, Ballestri S, Marchesini G, et al. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome. Dig Liver Dis 2015; 47: 181-190.
25. Carrascosa JM, Vilavella M, García-Doval I, et al. Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry. J Eur Acad Dermatol Venereol 2014; 28: 907-14.
26. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-56.
27. Ganzetti G, Campanati A, Molinelli E, et al. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. World J Cardiol 2016; 8: 120-31.
28. Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, et al. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20: 18070-91.
29. Panera N, Della Corte C, Crudele A, et al. Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. Expert Rev Gastroenterol Hepatol 2016; 10: 393-403.
30. Campanati A, Ganzetti G, Giuliodori K, et al. Serum levels of adipocytokines in psoriasis patients receiving tumor necrosis factor-α inhibitors: results of a retrospective analysis. Int J Dermatol 2015; 54: 839-45.
31. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-88.
32. Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol 2008; 103: 1036-42.
33. Calton EK, Keane KN, Newsholme P, et al. The impact of vitamin D levels on inflammatory status: a systematic review of immune cell studies. PLoS One 2015; 10: e0141770.
34. Eliades M, Spyrou E. Vitamin D: a new player in non-alcoholic fatty liver disease? World J Gastroenterol 2015; 21:1718-27.
35. Miele L, Liguori A, Marrone G, et al. Fatty liver and drugs: the two sides of the same coin. Eur Rev Med Pharmacol Sci 2017; 21 (1 Suppl): 86-94.
36. Daudén E, Blasco AJ2, Bonanad C, et al. Position statement for the management of comorbidities in psoriasis. J Eur Acad Dermatol Venereol 2018; 32: 2058-2073.
37. Daudén E, Castañeda S, Suárez C, et al. Abordaje integral de la comorbilidad del paciente con psoriasis. Actas Dermosifiliogr 2012; 103 Suppl 1:1-64.
38. Mofrad P, Contos MJ, Haque M, et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology 2003; 37: 1286-1292.
39. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388-402.
40. Gisondi P, Barba E, Girolomoni G, et al. Non-alcoholic fatty liver disease fibrosis score in patients with psoriasis. J Eur Acad Dermatol Venereol 2016; 30: 282-7.
41. Silva FS, Ribeiro MP, Santos MS, et al. Acitretin affects bioenergetics of liver mitochondria and promotes mitochondrial permeability transition: potential mechanisms of hepatotoxicity. Toxicology 2013; 306: 93-100.
42. Erarslan E, Ekiz F, Uz B, et al. Effects of erdosteine on cyclosporine-A-induced hepatotoxicity in rats. Drug Chem Toxicol 2011; 34: 32-7.
43. Helliwell PS, Taylor WJ; CASPAR Study Group. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions. J Rheumatol 2008; 35: 472-6.
44. Hardwick RN, Clarke JD, Lake AD, et al. Increased susceptibility to methotrexate-induced toxicity in nonalcoholic steatohepatitis. Toxicological Sci 2014; 142: 45-55.
45. Alfageme F, Bermejo A, Calvo JL, et al. [Cost Effectiveness of Treatments of Psoriasis with a PASI 75 and one Period of 12 Weeks]. Rev Esp Salud Publica 2016; 13; 90: E15.
46. Miyata M, Kuroda M, Unakami M, et al. Validation of the Fibrosis-4 (FIB-4) index in the diagnosis of liver disease of rheumatoid arthritis patients treated with methotrexate. Mod Rheumatol 2018; 31: 1-20.
47. Cheng HS, Rademaker M. Monitoring methotrexate-induced liver fibrosis in patients with psoriasis: utility of transient elastography. Psoriasis (Auckl) 2018; 8: 21-29.
48. Kim TY, Kim JY, Sohn JH, et al. Assessment of substantial liver fibrosis by real-time shear wave elastography in Methotrexate-treated patients with Rheumatoid Arthritis. J Ultrasound Med 2015; 34: 1621-30.
49. Al-Mutairi N, Shabaan D. Effects of tumor necrosis factor α inhibitors extend beyond psoriasis: insulin sensitivity in psoriasis patients with type 2 diabetes mellitus. Cutis 2016; 97: 235-41.
50. Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol 2013; 168: 609-16.
51. Ganzetti G, Campanati A, Offidani A. Psoriasis, non-alcoholic fatty liver disease, and cardiovascular disease: Three different diseases on a unique background. World J Cardiol 2016; 8: 120-131.
52. Campanati A, Ganzetti G, Di Sario A, et al. The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis. J Gastroenterol 2013; 48: 839-846.
53. Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). Z Gastroenterol 2008; 46: 1369-71.
54. Tang Y, Bian Z, Zhao L, et al. Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease. Clin Exp Immunol 2011; 166: 281-90.
55. Sourianarayanane A, Garg G, Smith TH, et al. Risk factors of non-alcoholic fatty liver disease in patients with inflammatory bowel disease. J Crohns Colitis. 2013; 7: e279-85.